INmune Bio (INMB) Competitors $2.30 -0.23 (-9.09%) Closing price 04:00 PM EasternExtended Trading$2.27 -0.03 (-1.30%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. CRDF, MDWD, EPRX, SOPH, INBX, YMAB, ACIU, VOR, SCPH, and IMABShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Cardiff Oncology (CRDF), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), SOPHiA GENETICS (SOPH), Inhibrx Biosciences (INBX), Y-mAbs Therapeutics (YMAB), AC Immune (ACIU), Vor Biopharma (VOR), scPharmaceuticals (SCPH), and I-Mab (IMAB). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Cardiff Oncology MediWound Eupraxia Pharmaceuticals SOPHiA GENETICS Inhibrx Biosciences Y-mAbs Therapeutics AC Immune Vor Biopharma scPharmaceuticals I-Mab INmune Bio (NASDAQ:INMB) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Does the media favor INMB or CRDF? In the previous week, INmune Bio had 21 more articles in the media than Cardiff Oncology. MarketBeat recorded 23 mentions for INmune Bio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.78 beat INmune Bio's score of -0.41 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 8 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, INMB or CRDF? INmune Bio has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K5,423.40-$42.08M-$1.93-1.19Cardiff Oncology$680K357.11-$45.43M-$0.92-3.97 Do analysts rate INMB or CRDF? INmune Bio presently has a consensus price target of $18.40, indicating a potential upside of 700.00%. Cardiff Oncology has a consensus price target of $9.88, indicating a potential upside of 170.55%. Given INmune Bio's higher probable upside, equities research analysts plainly believe INmune Bio is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Cardiff Oncology 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility and risk, INMB or CRDF? INmune Bio has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Do institutionals and insiders hold more shares of INMB or CRDF? 12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 35.7% of INmune Bio shares are owned by insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is INMB or CRDF more profitable? INmune Bio has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,308.50%. Cardiff Oncology's return on equity of -76.45% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -119.35% -89.37% Cardiff Oncology -8,308.50%-76.45%-62.85% SummaryCardiff Oncology beats INmune Bio on 9 of the 17 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.67M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E Ratio-1.1920.3027.1920.03Price / Sales5,423.40251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book1.597.397.925.55Net Income-$42.08M-$55.04M$3.17B$248.49M7 Day Performance-0.43%3.01%2.18%5.37%1 Month Performance-69.82%-0.21%1.25%6.63%1 Year Performance-70.63%4.48%33.90%21.20% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.5533 of 5 stars$2.30-9.1%$18.40+700.0%-66.7%$59.67M$10K-1.1910High Trading VolumeCRDFCardiff Oncology1.6682 of 5 stars$3.15flat$9.88+213.5%+65.4%$209.57M$680K-3.4220MDWDMediWound1.5971 of 5 stars$19.37+0.6%$31.80+64.2%-0.7%$209.39M$20.22M-9.2780News CoverageEPRXEupraxia Pharmaceuticals2.4876 of 5 stars$5.76+8.7%$11.00+91.0%+117.3%$207.13MN/A-7.5829Gap UpHigh Trading VolumeSOPHSOPHiA GENETICS2.3233 of 5 stars$3.10+0.3%$7.00+125.8%-35.0%$206.74M$65.17M-3.10520INBXInhibrx Biosciences0.9852 of 5 stars$14.27-1.1%N/A+26.3%$206.63M$200K0.12166YMABY-mAbs Therapeutics3.1236 of 5 stars$4.51-4.0%$15.60+245.9%-62.2%$204.21M$87.68M-7.05150ACIUAC Immune1.9491 of 5 stars$2.03+1.0%$12.00+491.1%-42.6%$203.83M$28.30M-3.50140VORVor Biopharma3.9366 of 5 stars$1.62+52.8%$5.63+247.4%+107.6%$202.44MN/A-0.98140Gap UpHigh Trading VolumeSCPHscPharmaceuticals4.12 of 5 stars$3.81-1.6%$14.00+267.5%-10.0%$201.14M$41.98M-1.9930Positive NewsIMABI-Mab2.8659 of 5 stars$2.42-5.8%$6.00+147.9%+39.4%$197.62M$3.89M0.00380Gap Up Related Companies and Tools Related Companies Cardiff Oncology Competitors MediWound Competitors Eupraxia Pharmaceuticals Competitors SOPHiA GENETICS Competitors Inhibrx Biosciences Competitors Y-mAbs Therapeutics Competitors AC Immune Competitors Vor Biopharma Competitors scPharmaceuticals Competitors I-Mab Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
